|
|
Volumn 18, Issue 6, 2009, Pages
|
|
Managing adverse events in the use of bevacizumab and chemotherapy.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
PACLITAXEL;
BLEEDING;
BREAST TUMOR;
CHEMICALLY INDUCED DISORDER;
DRUG APPROVAL;
HEART DISEASE;
HOSPITALIZATION;
HUMAN;
HYPERTENSION;
INTESTINE PERFORATION;
METHODOLOGY;
PHASE 3 CLINICAL TRIAL;
PROTEINURIA;
REVIEW;
SAFETY;
THROMBOEMBOLISM;
TREATMENT OUTCOME;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG APPROVAL;
HEART DISEASES;
HEMORRHAGE;
HUMANS;
HYPERTENSION;
INTESTINAL PERFORATION;
PACLITAXEL;
PROTEINURIA;
RESEARCH DESIGN;
SAFETY;
SEVERITY OF ILLNESS INDEX;
THROMBOEMBOLISM;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 65349108636
PISSN: 09660461
EISSN: None
Source Type: Journal
DOI: 10.12968/bjon.2009.18.6.40767 Document Type: Review |
|
Times cited : (10)
|
|
References (25)
|
